|
US5677437A
(en)
|
1990-07-27 |
1997-10-14 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
|
ES2083593T3
(es)
|
1990-08-03 |
1996-04-16 |
Sterling Winthrop Inc |
Compuestos y metodos para inhibir la expresion de genes.
|
|
US7015315B1
(en)
|
1991-12-24 |
2006-03-21 |
Isis Pharmaceuticals, Inc. |
Gapped oligonucleotides
|
|
US5714331A
(en)
|
1991-05-24 |
1998-02-03 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
|
|
US5719262A
(en)
|
1993-11-22 |
1998-02-17 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having amino acid side chains
|
|
US5539082A
(en)
|
1993-04-26 |
1996-07-23 |
Nielsen; Peter E. |
Peptide nucleic acids
|
|
US5633360A
(en)
|
1992-04-14 |
1997-05-27 |
Gilead Sciences, Inc. |
Oligonucleotide analogs capable of passive cell membrane permeation
|
|
EP0642589A4
(en)
|
1992-05-11 |
1997-05-21 |
Ribozyme Pharm Inc |
METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
|
|
US5977343A
(en)
|
1992-05-14 |
1999-11-02 |
Ribozyme Pharmaceuticals, Inc. |
Synthesis, deprotection, analysis and purification of RNA and ribozymes
|
|
CA2159629A1
(en)
|
1993-03-31 |
1994-10-13 |
Sanofi |
Oligonucleotides with amide linkages replacing phosphodiester linkages
|
|
US5753613A
(en)
|
1994-09-30 |
1998-05-19 |
Inex Pharmaceuticals Corporation |
Compositions for the introduction of polyanionic materials into cells
|
|
US5820873A
(en)
|
1994-09-30 |
1998-10-13 |
The University Of British Columbia |
Polyethylene glycol modified ceramide lipids and liposome uses thereof
|
|
US6001311A
(en)
|
1997-02-05 |
1999-12-14 |
Protogene Laboratories, Inc. |
Apparatus for diverse chemical synthesis using two-dimensional array
|
|
US6054576A
(en)
|
1997-10-02 |
2000-04-25 |
Ribozyme Pharmaceuticals, Inc. |
Deprotection of RNA
|
|
ATE443528T1
(de)
|
1998-01-05 |
2009-10-15 |
Univ Washington |
Erhöhter transport unter benutzung membranzerstörender stoffe
|
|
US7273933B1
(en)
|
1998-02-26 |
2007-09-25 |
Isis Pharmaceuticals, Inc. |
Methods for synthesis of oligonucleotides
|
|
US6867294B1
(en)
|
1998-07-14 |
2005-03-15 |
Isis Pharmaceuticals, Inc. |
Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
|
|
US6995259B1
(en)
|
1998-10-23 |
2006-02-07 |
Sirna Therapeutics, Inc. |
Method for the chemical synthesis of oligonucleotides
|
|
US6465628B1
(en)
|
1999-02-04 |
2002-10-15 |
Isis Pharmaceuticals, Inc. |
Process for the synthesis of oligomeric compounds
|
|
US7321029B2
(en)
|
2000-01-21 |
2008-01-22 |
Geron Corporation |
2′-arabino-fluorooligonucleotide N3′→P5′ phosphoramidates: their synthesis and use
|
|
DE60144479D1
(https=)
|
2000-09-01 |
2011-06-01 |
Ribozyme Pharm Inc |
|
|
US20040259247A1
(en)
|
2000-12-01 |
2004-12-23 |
Thomas Tuschl |
Rna interference mediating small rna molecules
|
|
US20020130430A1
(en)
|
2000-12-29 |
2002-09-19 |
Castor Trevor Percival |
Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
|
|
EP2017338A1
(en)
|
2001-05-24 |
2009-01-21 |
Genzyme Corporation |
Muscle-specific expression vectors
|
|
US7060498B1
(en)
|
2001-11-28 |
2006-06-13 |
Genta Salus Llc |
Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
|
|
US20030215395A1
(en)
|
2002-05-14 |
2003-11-20 |
Lei Yu |
Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
|
|
US6989442B2
(en)
|
2002-07-12 |
2006-01-24 |
Sirna Therapeutics, Inc. |
Deprotection and purification of oligonucleotides and their derivatives
|
|
WO2004020605A2
(en)
|
2002-08-29 |
2004-03-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Circular nucleic acid vectors, and methods for making and using the same
|
|
EP2305812A3
(en)
*
|
2002-11-14 |
2012-06-06 |
Dharmacon, Inc. |
Fuctional and hyperfunctional sirna
|
|
US7358223B2
(en)
|
2004-10-04 |
2008-04-15 |
Nitto Denko Corporation |
Biodegradable cationic polymers
|
|
JP2008526229A
(ja)
|
2005-01-06 |
2008-07-24 |
ベニテック，インコーポレーテッド |
幹細胞の維持のためのＲＮＡｉ剤
|
|
JP5042863B2
(ja)
|
2005-02-14 |
2012-10-03 |
サーナ・セラピューティクス・インコーポレイテッド |
生物学的に活性な分子をデリバリーするための脂質ナノ粒子系組成物および方法
|
|
US8110184B2
(en)
*
|
2005-09-30 |
2012-02-07 |
University Of Kentucky Research Foundation |
Ex vivo and in vivo methods and related compositions for generating hematopoietic stem cell populations
|
|
EP2014281A1
(en)
|
2007-06-19 |
2009-01-14 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Use of inhibitors of sirtuins and/or ampk for the preparation of a medicament for the treatment of polyalanine diseases.
|
|
US20110224447A1
(en)
|
2008-08-18 |
2011-09-15 |
Bowman Keith A |
Novel Lipid Nanoparticles and Novel Components for Delivery of Nucleic Acids
|
|
CN104119242B
(zh)
|
2008-10-09 |
2017-07-07 |
泰米拉制药公司 |
改善的氨基脂质和递送核酸的方法
|
|
WO2010080724A1
(en)
|
2009-01-12 |
2010-07-15 |
Merck Sharp & Dohme Corp. |
Novel lipid nanoparticles and novel components for delivery of nucleic acids
|
|
AU2010223967B2
(en)
|
2009-03-12 |
2015-07-30 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
|
EP2467357B1
(en)
|
2009-08-20 |
2016-03-30 |
Sirna Therapeutics, Inc. |
Novel cationic lipids with various head groups for oligonucleotide delivery
|
|
JP2013519869A
(ja)
|
2010-02-10 |
2013-05-30 |
ノバルティス アーゲー |
筋肉成長のための方法および化合物
|
|
RU2639549C2
(ru)
|
2010-12-30 |
2017-12-21 |
ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи |
Молекулы нуклеиновых кислот, которые придают устойчивость к насекомым-вредителям отряда жесткокрылых
|
|
KR101454425B1
(ko)
*
|
2012-10-11 |
2014-11-03 |
포항공과대학교 산학협력단 |
미리세틴을 유효성분으로 포함하는 운동수행능력 증강용 조성물
|
|
WO2014077693A1
(en)
|
2012-11-16 |
2014-05-22 |
Academisch Ziekenhuis Leiden H.O.D.N. Lumc |
Means and methods for reducing an effect of aging in a mammalian cell
|
|
KR101683964B1
(ko)
*
|
2014-05-29 |
2016-12-09 |
연세대학교 산학협력단 |
Daxx의 발현을 억제하는 핵산 분자, TRAIL 유전자 및 Bcl-xL 의 발현을 억제하는 핵산 분자를 포함하는 재조합 발현 벡터
|
|
CA3020754C
(en)
|
2016-04-14 |
2023-07-25 |
Benitec Biopharma Limited |
Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof
|